Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 2/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | HPN | P05981 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.31 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10801442 | 1.00 | MAPK1 (0.39) | MAPK1NPY5RPDE7ALCKJAK3 | |
| SCHEMBL21222493 | 1.00 | MAPK1 (0.39) | MAPK1NPY5RPDE7ALCKJAK3 | |
| Hydrochloric Acid SCHEMBL10811192 | 0.98 | MAPK1 (0.38) | MAPK1NPY5RPDE7ALCKJAK3 | |
| Hydrochloric Acid SCHEMBL11148872 | 0.98 | MAPK1 (0.38) | MAPK1NPY5RPDE7ALCKJAK3 | |
| SCHEMBL13455119 | 0.90 | NPY5R (0.41) | MAPK1NPY5RPDE7ALCKJAK3 | |
| SCHEMBL15448411 | 0.82 | NPY5R (0.38) | NPY5RPDE7AF2F10HPN | |
| SCHEMBL23714592 | 0.82 | MAPK1 (0.43) | MAPK1NPY5RPDE7ALCKJAK3 | |
| SCHEMBL17001889 | 0.80 | CHRM2 (0.41) | NPY5RPDE7A | |
| SCHEMBL13455158 | 0.78 | NPY5R (0.43) | MAPK1NPY5RPDE7APER2 | |
| SCHEMBL2853627 | 0.77 | TP53 (0.42) | NPY5RPDE7ALCKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
| US-4634713-A | ADRENERGIC BLOCKING AGENTS | CIBA-GEIGY CORPORATION (US) | 1987-01-06 | — | — | US | disclosed |
| EP-0096006-A2 | 3-(Ureidocyclohexylamino)-propane-1,2-diol derivatives, process for their preparation, pharmaceutical preparations containing these compounds and their therapeutical use | CIBA-GEIGY AG (CH) | 1983-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | HPGDS, PTGDR, PTGER1 | MAPK1 2082/4885NPY5R 968/4885PDE7A 905/4885 |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | HPGDS, PTGDR, PTGER1 | MAPK1 2082/4885NPY5R 968/4885PDE7A 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.